BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 12, 2010
View Archived Issues
Dicerna Raises $25M Series B to Fund RNAi Cancer Program
Read More
Aegerion Re-Files $86M IPO to Back Cholesterol Drug
Read More
Amgen's Vectibix Disappoints in Head/Neck Cancer Trial
Read More
Other News To Note
Read More
Stock Movers
Read More
Clinic Roundup
Read More
Alectos to Study Alzheimer's Target in Merck $289M Deal
Alectos Therapeutics Inc. will receive up to $289 million in an up-front fee and milestone payments under a collaboration with Merck & Co. to study a potential non-amyloid approach to treat Alzheimer's disease. (BioWorld Today)
Read More
FDA Panel Gives Thumbs Up for Valeant Epilepsy Drug
Read More